Abstract
Postoperative combined-modality therapy with fluorouracil (5-FU) and radiation therapy is accepted practice for high-risk rectal cancer. Postoperative pelvic radiotherapy alone may improve pelvic control, but is not associated with an improvement in survival. Protracted infusional 5-FU has been associated with decreased tumor recurrence and improved survival when combined with postoperative adjuvant pelvic radiotherapy. The use of new drugs and alternative ways of administering 5-FU is desirable. UFT plus leucovorin is an oral 5-FU prodrug with efficacy equal to 5-FU plus leucovorin in metastatic colorectal cancer. A combination of postoperative adjuvant UFT plus leucovorin concurrent with radiation therapy should be feasible, and the design of an ongoing phase I trial is presented.
Original language | English (US) |
---|---|
Pages (from-to) | 59-62 |
Number of pages | 4 |
Journal | ONCOLOGY |
Volume | 14 |
Issue number | 10 SUPPL. 9 |
State | Published - 2000 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research